Efficacy of SIGMAR1-based therapy in the early treatment of confirmed mild symptomatic COVID-19 patients

Simple item page
dc.contributor.affiliationUniversidade de Santiago de Compostela. Centro de Investigación en Medicina Molecular e Enfermidades Crónicas (CiMUS)
dc.contributor.affiliationUniversidade de Santiago de Compostela. Departamento de Farmacoloxía, Farmacia e Tecnoloxía Farmacéutica
dc.contributor.authorGrau, Santiago
dc.contributor.authorVela, José Miguel
dc.contributor.authorGurt, Alba
dc.contributor.authorBarceló Vidal, Jaime
dc.contributor.authorOjeda, Fabiola
dc.contributor.authorLópez, Iago
dc.contributor.authorGómez García, Laura
dc.contributor.authorLoza García, María Isabel
dc.contributor.authorMartín García, Elena
dc.contributor.authorMaldonado, Rafael
dc.contributor.authorMonfort, Jordi
dc.date.accessioned2026-01-20T12:33:41Z
dc.date.available2026-01-20T12:33:41Z
dc.date.issued2024-02
dc.description.peerreviewedSI
dc.description.sponsorshipThis work was supported by the Spanish “Minsterio de Ciencia e Innovación (MICIN), Agencia Estatal de Investigación (AEI)” (PID2020-120029GB-I00/MICIN/AEI/10.13039/501100011033) to RM; the “Generalitat de Catalunya, AGAUR” (2017 SGR-669) to RM; the “ICREA-Acadèmia” (2020) to RM; and the Spanish “Instituto de Salud Carlos III, RETICS-RTA” (RD16/0017/0020) to RM. We gratefully acknowledge grant support from Xunta de Galicia through the call for proposals RESCATA-COVID (IN845D 2020/19) and the European Regional Development Fund (ERDF). This work has also been co-financed by the Ministry of Science and Innovation, Spain, with funds from the European Union NextGenerationEU (PRTRC17.I1) and the Autonomous Community of Galicia within the framework of the 2023 Biotechnology Plan Applied to Health. Finally, this work received partial financial support from Esteve Pharmaceuticals S.A.
dc.identifier.citationSantiago Grau, José Miguel Vela, Alba Gurt, Jaime Barceló-Vidal, Fabiola Ojeda, Iago López, Laura Gómez-García, María Isabel Loza, Elena Martín-García, Rafael Maldonado, Jordi Monfort, Efficacy of SIGMAR1-based therapy in the early treatment of confirmed mild symptomatic COVID-19 patients, Journal of Infection, Volume 88, Issue 2, 2024, Pages 187-190, ISSN 0163-4453, https://doi.org/10.1016/j.jinf.2023.11.008
dc.identifier.doi10.1016/j.jinf.2023.11.008
dc.identifier.essn1532-2742
dc.identifier.urihttps://hdl.handle.net/10347/45285
dc.issue.number2
dc.journal.titleJournal of Infection
dc.language.isoeng
dc.page.final190
dc.page.initial187
dc.publisherElsevier
dc.relation.projectIDinfo:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/PID2020-120029GB-I00/ES/NUEVOS ABORDAJES PARA ESCLARECER LOS MECANISMOS BIOLOGICOS SUBYACENTES A LA PERDIDA DE CONTROL SOBRE LA INGESTA DE COMIDA
dc.relation.publisherversionhttps://doi.org/10.1016/j.jinf.2023.11.008
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internationalen
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectSIGMAR1-based therapy
dc.subjectCOVID-19
dc.subjectTreatment
dc.titleEfficacy of SIGMAR1-based therapy in the early treatment of confirmed mild symptomatic COVID-19 patients
dc.typejournal article
dc.type.hasVersionAM
dc.volume.number88
dspace.entity.typePublication
relation.isAuthorOfPublication7765cb9b-b630-44dc-9477-dd266a62bb3c
relation.isAuthorOfPublication.latestForDiscovery7765cb9b-b630-44dc-9477-dd266a62bb3c

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
2024_JInf_Grau_Efficacy_am.pdf
Size:
2.53 MB
Format:
Adobe Portable Document Format
Download

Collections

Farmacoloxía, Farmacia e Tecnoloxía Farmacéutica
Centro de Investigación en Medicina Molecular e Enfermidades Crónicas (CiMUS)